{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:28:45Z","timestamp":1778502525227,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000971","name":"Diabetes Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.diabres.2023.111082","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T17:00:39Z","timestamp":1703869239000},"page":"111082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["COX2 inhibitor use and type 2 diabetes treatment intensification: A registry-based cohort study"],"prefix":"10.1016","volume":"207","author":[{"given":"George S.Q.","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jedidiah I.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie L.","family":"Trevaskis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianna J.","family":"Magliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Windsor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenni","family":"Ilom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2023.111082_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2023.111082_b0010","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","article-title":"Treatment of type 2 diabetes: challenges, hopes, and anticipated successes","volume":"9","author":"Nauck","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.111082_b0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/5584_2020_516","article-title":"Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus","volume":"1307","author":"G\u00f6k\u00e7ay Canpolat","year":"2021","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.diabres.2023.111082_b0020","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Banting","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2023.111082_b0025","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2337\/dbi17-0045","article-title":"A Global Overview of Precision Medicine in Type 2 Diabetes","volume":"67","author":"Fitipaldi","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2023.111082_b0030","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/oby.2008.674","article-title":"COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver","volume":"17","author":"Hsieh","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.diabres.2023.111082_b0035","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s42255-021-00457-w","article-title":"Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity","volume":"3","author":"Cao","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.diabres.2023.111082_b0040","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1042\/EBC20160042","article-title":"Adipose tissue development and the molecular regulation of lipid metabolism","volume":"60","author":"Raajendiran","year":"2016","journal-title":"Essays Biochem"},{"key":"10.1016\/j.diabres.2023.111082_b0045","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.4049\/jimmunol.1500221","article-title":"Collecting lymphatic vessel permeability facilitates adipose tissue inflammation and distribution of antigen to lymph node-homing adipose tissue dendritic cells","volume":"194","author":"Kuan","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.diabres.2023.111082_b0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13410-015-0355-7","article-title":"Targeting inflammation using celecoxib with glimepiride in the treatment of obese type 2 diabetic Egyptian patients","volume":"37","author":"El-Bahrawy","year":"2015","journal-title":"Int J Diabetes Devel Countries"},{"key":"10.1016\/j.diabres.2023.111082_b0055","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/imj.13792","article-title":"Prevalence of diabetes in Australia: insights from the fremantle diabetes study phase II","volume":"48","author":"Davis","year":"2018","journal-title":"Intern Med J"},{"key":"10.1016\/j.diabres.2023.111082_b0060","unstructured":"Australian National Diabetes Audit - Australian Quality Clinical Audit 2021 Annual Report."},{"key":"10.1016\/j.diabres.2023.111082_b0065","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc21-2268","article-title":"Trends in the incidence of hospitalization for major diabetes-related complications in people with type 1 and type 2 diabetes in australia, 2010\u20132019","volume":"45","author":"Morton","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.111082_b0070","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s13104-015-1616-8","article-title":"The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers","volume":"8","author":"Mellish","year":"2015","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.diabres.2023.111082_b0075","unstructured":"ATC\/DDD Index 2022. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology."},{"key":"10.1016\/j.diabres.2023.111082_b0080","unstructured":"Management of type 2 diabetes: A handbook for general practice. East Melbourne, Vic: The Royal Australian College of General Practitioners; 2020."},{"key":"10.1016\/j.diabres.2023.111082_b0085","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/dme.14149","article-title":"Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?","volume":"37","author":"Wood","year":"2020","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2023.111082_b0090","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"9. pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020","volume":"43","author":"American","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.111082_b0095","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/bmjqs-2020-012026","article-title":"Adherence to guideline-recommended HbA1c testing frequency and better outcomes in patients with type 2 diabetes: a 5-year retrospective cohort study in Australian general practice","volume":"30","author":"Imai","year":"2021","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.diabres.2023.111082_b0100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00125-020-05304-3","article-title":"The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study","volume":"64","author":"Morton","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2023.111082_b0105","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.cjca.2021.06.014","article-title":"Recategorization of non-aspirin nonsteroidal anti-inflammatory drugs according to clinical relevance: abandoning the traditional nsaid terminology","volume":"37","author":"Bonnesen","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.diabres.2023.111082_b0110","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bcp.13792","article-title":"Prevalence and incidence of prescription opioid analgesic use in Australia","volume":"85","author":"Lalic","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.diabres.2023.111082_b0115","article-title":"Arthritis and pain. current approaches in the treatment of arthritic pain","author":"Kidd","year":"20079214","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.diabres.2023.111082_b0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jpain.2015.12.008","volume":"17","author":"Chou","year":"2016","journal-title":"J Pain"},{"key":"10.1016\/j.diabres.2023.111082_b0125","doi-asserted-by":"crossref","first-page":"e021122","DOI":"10.1136\/bmjopen-2017-021122","article-title":"The validity of the Rx-Risk comorbidity index using medicines mapped to the anatomical therapeutic chemical (atc) classification system","volume":"8","author":"Pratt","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.diabres.2023.111082_b0130","unstructured":"Australian Bureau of Statistics Socio-Economic Index for Areas (SEIFA). Technical Paper. 2016."},{"key":"10.1016\/j.diabres.2023.111082_b0135","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/(SICI)1097-0258(19970330)16:6<611::AID-SIM437>3.0.CO;2-T","article-title":"An empirical comparison of statistical tests for assessing the proportional hazards assumption of Cox's model","volume":"16","author":"Ng'andu","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.diabres.2023.111082_b0140","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.diabres.2023.111082_b0145","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.diabres.2023.111082_b0150","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"10.1016\/j.diabres.2023.111082_b0155","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1037\/a0019623","article-title":"Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research","volume":"15","author":"Harder","year":"2010","journal-title":"Psychol Methods"},{"issue":"38","key":"10.1016\/j.diabres.2023.111082_b0160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1467-9531.2008.00204.x","article-title":"A diagnostic routine for the detection of consequential heterogeneity of causal effects","volume":"38","author":"Morgan","year":"2008","journal-title":"Sociol Methodol"},{"key":"10.1016\/j.diabres.2023.111082_b0165","doi-asserted-by":"crossref","unstructured":"Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013;66:S84-S90 e1.","DOI":"10.1016\/j.jclinepi.2013.01.013"},{"key":"10.1016\/j.diabres.2023.111082_b0170","first-page":"93","article-title":"WHO guidelines for the use of analgesics in cancer pain","volume":"7","author":"Ventafridda","year":"1985","journal-title":"Int J Tissue React"},{"key":"10.1016\/j.diabres.2023.111082_b0175","doi-asserted-by":"crossref","first-page":"e004580","DOI":"10.1161\/CIRCOUTCOMES.118.004580","article-title":"Importance of considering competing risks in time-to-event analyses: application to stroke risk in a retrospective cohort study of elderly patients with atrial fibrillation","volume":"11","author":"Abdel-Qadir","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.diabres.2023.111082_b0180","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11892-022-01473-0","article-title":"The clash of two epidemics: the relationship between opioids and glucose metabolism","volume":"22","author":"Koekkoek","year":"2022","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.diabres.2023.111082_b0185","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2337\/diacare.28.1.65","article-title":"The effect of chronic pain on diabetes patients' self-management","volume":"28","author":"Krein","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.111082_b0190","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.diabet.2010.06.001","article-title":"Physical exercise for the prevention and treatment of type 2 diabetes","volume":"36","author":"Sanz","year":"2010","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2023.111082_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.794273","article-title":"Treatment dynamics in people who initiate metformin or sulfonylureas for type 2 diabetes: a national cohort study","volume":"12","author":"Wood","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabres.2023.111082_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103422","article-title":"Drug repurposing using real-world data","volume":"28","author":"Tan","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.diabres.2023.111082_b0205","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/bmj.39024.487720.68","article-title":"What have we learnt from Vioxx?","volume":"334","author":"Krumholz","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2023.111082_b0210","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bcp.13048","article-title":"Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective","volume":"82","author":"Patrono","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.diabres.2023.111082_b0215","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","article-title":"Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2","volume":"296","author":"McGettigan","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2023.111082_b0220","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/FJC.0b013e318157f72d","article-title":"COX-2 inhibitors and cardiovascular risk","volume":"50","author":"Funk","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.diabres.2023.111082_b0225","first-page":"e1144","article-title":"Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue","volume":"9","author":"Varga","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.diabres.2023.111082_b0230","doi-asserted-by":"crossref","first-page":"e00817","DOI":"10.1002\/prp2.817","article-title":"Kidney damage from nonsteroidal anti-inflammatory drugs-Myth or truth? review of selected literature","volume":"9","author":"Drozdzal","year":"2021","journal-title":"Pharmacol Res Perspect"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723008458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723008458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T17:03:53Z","timestamp":1740243833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822723008458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":46,"alternative-id":["S0168822723008458"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2023.111082","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COX2 inhibitor use and type 2 diabetes treatment intensification: A registry-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2023.111082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111082"}}